Prior to joining Eris, Ranganathan was Commercial Director, Women's Health, Metabolics, and International Business at Abbott India Limited
Lupin is committed to providing new affordable treatment options to healthcare providers and patients
The investment will upgrade and expand production capabilities at Lilly Lebanon API and Lilly Lebanon Advanced Therapies
But acquisition charges drag earnings into loss
American College of Cardiology and Korean Society of Cardiology convene global experts to address rising cardiometabolic burden
GoodRx at a starting price of $149 per month—aligned with the lowest available discounted cash price at launch. The rollout includes nationwide pharmacy access
In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga
Immediate U.S. launch planned for Farxiga®-equivalent diabetes drug; opportunity pegged at $10.2 billion in annual market size
Immediate opportunity in the $10.2 billion U.S. market as the diabetes therapy will be manufactured at Zydus’ SEZ Ahmedabad facility
They also differentiated the innovator biologic Semaglutide molecule from newer synthetic or chemical generic versions entering the market
Subscribe To Our Newsletter & Stay Updated
